What's in Universitätsklinikum Hamburg-Eppendorf's pipeline?

Universitätsklinikum Hamburg-Eppendorf has 4 drugs in our index: 1 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Universitätsklinikum Hamburg-Eppendorf's portfolio?

Top competitors by shared drug class: AstraZeneca, Amgen, Asan Medical Center, Alliance for Clinical Trials in Oncology, Beijing Friendship Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/universit-tsklinikum-hamburg-eppendorf.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Universitätsklinikum Hamburg-Eppendorf — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Universitätsklinikum Hamburg-Eppendorf pipeline: 1 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Cefuroxime 4,5g	Cefuroxime 4,5g	marketed
Adjuvant Nivolumab and Ipilimumab	Adjuvant Nivolumab and Ipilimumab	phase 3	PD-1 inhibitor and CTLA-4 inhibitor combination	PD-1 and CTLA-4	Oncology
CMF Chemotherapy	CMF Chemotherapy	phase 3	Combination chemotherapy regimen		Oncology
ERVEBO® (rVSV∆G-ZEBOV-GP)	ERVEBO® (rVSV∆G-ZEBOV-GP)	phase 3	Live attenuated viral vaccine	Ebola virus glycoprotein (ZEBOV-GP)	Immunology / Infectious Disease

Therapeutic area mix

Oncology · 2
Immunology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 2 shared drug classes
Amgen · 1 shared drug class
Asan Medical Center · 1 shared drug class
Alliance for Clinical Trials in Oncology · 1 shared drug class
Beijing Friendship Hospital · 1 shared drug class
Biomed Industries, Inc. · 1 shared drug class
Centers for Disease Control and Prevention · 1 shared drug class
Affiliated Cancer Hospital & Institute of Guangzhou Medical University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Universitätsklinikum Hamburg-Eppendorf:

Cite this brief

Drug Landscape (2026). Universitätsklinikum Hamburg-Eppendorf — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universit-tsklinikum-hamburg-eppendorf. Accessed 2026-06-10.